U.S., Dec. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07297797) titled 'Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension' on Dec. 09.
Brief Summary: This study aims to evaluate the efficacy and safety of HRS-9563 in patients with mild to moderate hypertension, and to explore its appropriate dosage.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Mild to Moderate Hypertension
Intervention:
DRUG: HRS-9563 Injection
HRS-9563 Injection
DRUG: sodium chloride injection
sodium chloride injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Published by HT Digital Content Services with permission from Hea...